Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adcetris brentuximab vedotin: Additional Phase I data

Additional data from 47 evaluable patients with newly diagnosed Hodgkin's lymphoma in an open-label, dose-escalation, North American Phase I trial showed that the rate of complete remissions was 95% in patients receiving Adcetris plus ABVD ( adriamycin, bleomycin, vinblastine and dacarbazine) (n=22) and 96% in

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE